Agios Interest Expense from 2010 to 2026

8AP Stock  EUR 25.00  0.60  2.34%   
Agios Pharmaceuticals' Interest Expense is increasing over the last several years with stable swings. Interest Expense is predicted to flatten to 0.00. Interest Expense is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. View All Fundamentals
 
Interest Expense  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
4.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Agios Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 116.6 M or Total Revenue of 65.8 M, as well as many indicators such as . Agios financial statements analysis is a perfect complement when working with Agios Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Agios Pharmaceuticals Technical models . Check out the analysis of Agios Pharmaceuticals Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Agios Stock

Agios Pharmaceuticals financial ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharmaceuticals security.